List of news related to Novo Nordisk NVO:

Title: Is Novo Nordisk (NVO) the Best Stock to Buy According to Jim Simons’ Renaissance Technologies?
URL: https://finance.yahoo.com/news/novo-nordisk-nvo-best-stock-205939112.html
Time Published: 2025-05-11T20:59:39Z
Description: We recently published a list of 15 Best Stocks to Buy According to Jim Simons’ Renaissance Technologies In this article, we are going to take a look at where...
--------------------------------------------------

Title: Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
URL: https://www.globenewswire.com/news-release/2025/05/09/3078140/0/en/Novo-Nordisk-A-S-Trading-in-Novo-Nordisk-shares-by-board-members-executives-and-associated-persons.html
Time Published: 2025-05-09T11:22:00Z
Full Content:
May 09, 2025 07:22 ET | Source: Novo Nordisk A/S Novo Nordisk A/S Bagsværd, Denmark, 9 May 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons. Please find below a statement of such trading in shares issued by Novo Nordisk. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 72,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube. Contacts for further information Media: Ambre James-Brown +45 3079 9289abmo@novonordisk.com Liz Skrbkova (US)+1 609 917 0632lzsk@novonordisk.com Investors: Jacob Martin Wiborg Rode+45 3075 5956jrde@novonordisk.com Ida Schaap Melvold +45 3077 5649idmg@novonordisk.com Sina Meyer +45 3079 6656azey@novonordisk.com Frederik Taylor Pitter +1 609 613 0568fptr@novonordisk.com Max Ung+45 +45 3077 6414 mxun@novonordisk.com Company Announcement No 15 / 2025 Attachment The REAL8 trial showed that after 52 weeks, once-weekly Sogroya® (somapacitan) had similar clinical outcomes and safety profile to once-daily Norditropin® (somatropin) in children born small for... 7 May 2025 - Financial report for the period 1 January 2025 to 31 March 2025 ...
--------------------------------------------------